A Randomized, Double-blind, Multi-center Phase 2 Trial of Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer

To assess whether any relative benefit on overall survival (OS) from the combination of denosumab and standard of care (SOC) versus SOC alone in non-small cell lung cancer (NSCLC) is associated with tumor RANK expression